相关实验视频

Updated: Jul 23, 2025

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

在神经退行过程中,TREM2受体通过与补充C1q结合来防止补充介导的突触损失

Li Zhong¹, Xuan Sheng¹, Wanbing Wang¹

¹Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen 361102, Fujian, China.

|July 13, 2023

概括

在骨髓细胞2 (TREM2) 上表达的触发受体通过结合补充C1q来保护阿尔茨海默病. 这种相互作用可以防止微质细胞过度消除突触,从而保持认知功能.

科学领域:

神经科学是一个神经科学.
免疫学免疫学免疫学
遗传学是一个遗传学.

背景情况:

在骨髓细胞2 (TREM2) 上表达的触发受体是阿尔茨海默病 (AD) 的关键风险基因.
人们对TREM2影响AD病变的确切机制尚不完全了解.
微质功能,包括突触修剪,都与神经退行有关.

研究的目的:

阐明TREM2在补充级联和阿尔茨海默病中的突触完整性中的功能作用.
为了确定TREM2和补充C1q之间的分子相互作用.
评估针对TREM2-C1q相互作用的治疗潜力.

主要方法:

在人类AD脑样本上进行免疫组织化学检测,以检测TREM2-C1q复合体.
生物化学测定证实TREM2与C1q结合.
在AD小鼠模型 (突变的人类陶氏体) 中进行的研究,Trem2的哈普洛缺陷.
在AD小鼠模型中使用TREM2衍生的.

主要成果:

TREM2直接与C1q结合,抑制了经典的补充级联.
人类AD大脑中存在TREM2-C1q复合体,与C3沉积和突触蛋白水平相关.
在小鼠中,Trem2 缺乏会增强微质突触吞,加速突触损失.
阻断C1q相互作用的TREM2可以在AD小鼠模型中挽救突触缺陷.

结论:

微质TREM2在预防神经退行症中过度补充介导的突触消除方面发挥着关键作用.
准TREM2-C1q相互作用为阿尔茨海默病提供了潜在的治疗策略.
这项研究为TREM2在AD的保护功能提供了新的机制性见解.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.在C1qq.C3 C3 C3 C3 C3 C3 C3 C3 C3 C3 C3 C3 C3 C3 C3 C3 C3 C3 C3 C3 在TREM2中,我们可以使用TREM2.补充补充补充补充补充补充补充.微质细胞中的微质细胞神经退行症的神经退行症发生突触损失.

更多相关视频

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures

Published on: March 18, 2021

A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes

A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes

Published on: February 5, 2018

相关概念视频

Enzyme-linked Receptors

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...

Complement System

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...